The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negativel...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunol
Autors principals: Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R., Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J., Marshall, Michael J. E., Cox, Kerry L., Turaj, Anna H., Cragg, Mark S., Klein, Christian, Carter, Matthew J., Tannheimer, Stacey
Format: Artigo
Idioma:Inglês
Publicat: AAI 2018
Matèries:
Clinical and Human Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857647/
https://ncbi.nlm.nih.gov/pubmed/29453281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1700323
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars